Jyong Biotech Ltd. Ordinary Shares (MENS) - Total Assets
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) holds total assets worth $37.67 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MENS equity financing ratio to measure how much of total assets are equity-financed.
Jyong Biotech Ltd. Ordinary Shares - Total Assets Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See Jyong Biotech Ltd. Ordinary Shares shareholders equity for net asset value and shareholders' equity analysis.
Jyong Biotech Ltd. Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Jyong Biotech Ltd. Ordinary Shares's total assets of $37.67 Million consist of 3.2% current assets and 96.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jyong Biotech Ltd. Ordinary Shares market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jyong Biotech Ltd. Ordinary Shares's current assets represent 3.2% of total assets in 2024, a decrease from 48.4% in 2020.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2024, down from 27.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Jyong Biotech Ltd. Ordinary Shares Competitors by Total Assets
Key competitors of Jyong Biotech Ltd. Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Jyong Biotech Ltd. Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.62 | 0.02 | 0.13 |
| Quick Ratio | 0.62 | 0.02 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.39 Million | $-11.73 Million | $-12.42 Million |
Jyong Biotech Ltd. Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Jyong Biotech Ltd. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 18.19 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | $6.37 Million |
| Market Capitalization | $115.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Jyong Biotech Ltd. Ordinary Shares's assets at a significant premium (18.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Jyong Biotech Ltd. Ordinary Shares's assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual total assets of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.37 Million | -22.82% |
| 2023-12-31 | $8.25 Million | -5.68% |
| 2022-12-31 | $8.74 Million | -7.28% |
| 2021-12-31 | $9.43 Million | -26.56% |
| 2020-12-31 | $12.84 Million | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more